Lower Reimbursement For Accelerated Approval Drugs May Get Push From ICER

 
• By Sarah Karlin-Smith

ICER President Steve Pearson expresses interest in setting drug costs for accelerated approval drugs low with price increases based on confirmatory evidence ahead of upcoming white paper from the group.

dollar sign with down arrow
ICER may soon suggest accelerated approval drugs start at low price points. • Source: Shutterstock

More from Pricing Debate

More from Market Access